Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business ...
Immunotherapy has transformed cancer treatment by harnessing the body's own immune system to fight disease. But many ...
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global ...
Immunotherapy has transformed cancer treatment by harnessing the body's own immune system to fight disease. But many ...
Large genomic study of feline tumors identifies shared mutations with human cancers, strengthening comparative oncology ...
News, features, and commentary about cancer-related issues ...
The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and ...
"When you hear directly from parents about what a wish meant to their child, it really hits home," says Ben O’Connell of Make ...